Redefining drug delivery.

NaDeNo’s drug delivery platform enables targeted delivery of hard-to-deliver drugs.

Our versatile drug delivery platform enable novel and differentiated drugs, and we are open to partnerships and co-developments with companies in need of a drug delivery technology

Numerous applicable drug classes

Successful encapsulation of numerous drug classes across indications with high unmet need and commercial potential.

Sustainable & scalable manufacturing

NaDeNo’s nanoparticles encapsulate the drug in a patented 1-step process without any chemical modification of the drug.

Adaptive surface targeting

By functionalizing the surface, the nanoparticles can achieve various forms of chemical and/or biological targeting.

Retention and controlled release

Proven retention following various local administration routes, combined with controlled release for sustained efficacy.

Lead asset

PACAB-002 to prevent recurrence in ovarian cancer

NaDeNo’s platform-enabled lead candidate PACAB-002 will start clinical investigation in a Phase I trial beginning Q1 2027. PACAB-002 is intended to eradicate peritoneal micrometastases for patients with high-grade serous ovarian cancer (HGSOC), the leading cause of high recurrence and poor survival.